Rosetta Genomics (ROSGQ)

[nicoausto]

It would appear sabby quietly dumped for chump change. Thought they were better than that honestly. I thought those guys were ballers with standards. Guess not

[OptimusPrime555]

This company is BANKRUPT!

Prof: https://www.otcmarkets.com/stock/ROSGQ/overview

[ICURhere2]

Surprised no one is talking about this.

[ICURhere2]

What's going on here?

[Mathmos]

Volume since Days. What is going on?
Reinstatement?

[Mathmos]

$ROSGQ did it Today! 0,0346 &
Break of 52 Week High at 0.0188!

[nicoausto]

Right on buddy. I do not think this will pop off anytime soon, but when it does it will come alive in a big way as the most recent filings are rather intriguing. Seems like a good entry at these levels so i took a starter. We'll see how it goes, best to you and everyone else taking a gamble on this lotto

[Mathmos]

i am with you. MM are more active here than the last 6 month!

[nicoausto]

Breakout imminent imho

[Golden Cross]

Something may be brewing here again..

[Mathmos]

GM. Could someone in here be so kind please to Call ROSGQ Head OFFICE on 972-73-222-0700. I tried to get Information from their Twitter, but will no longer wait for their reply. If someone in here could please call them to find out which float is correct. OTC shows 1.87m. Ihub 1.87m. After their filing from 01/04/2019 i counted 6m. Got the feeling that they are locked and the 1.87m are correct. But will go secure here. And I need their Email Adress from their IR too. Could not find it on the www. I am in germany and it is not possible here to Call this Number. Thank you!

[NextGenCapCG]

Agreed there. I was looking around and see that a hedge fund called Sabby Management took a control position back around January. Not the biggest fund ever, but the principal of the fund just bought a $10mm palace in Miami so they are doing alright.

Obviously it could be part of a short strategy or something else, but anytime I see sophisticated money playing in OTC land, that interests me. Based on what I have read, it seems like Rosetta still owns the IP. They sold all their other assets. Assuming that money went to pay off balance sheet liabilities, it seems like this company could reinvigorate itself by licensing their patents and/or beginning operations again with (to your point) the help of some debt or equity capital from Wall Street. Especially because it seems that their tech has real utility.

I have a starter position already. Going to try to accumulate more shares at a reasonable price.

[Mathmos]

yes i know, and this are my thoughts too. Get some lotto in here as a reorganisation play. They are too busy to not need fresh money at some point. And the best way is to get this at wall street! The other variant could be, that an other player get´s into the shell of rosetta and this will blast the PPS too.

[NextGenCapCG]

Mathmos,

Do we know if this invention is "new" or whether they were just summarizing one of their inventions from their past years of operation?

Their website is super sketchy, which doesn't help confident. However, based on my understanding of their asset sale, they still own all the IP which could be monumental if they can straighten everything else out.

[Mathmos]

http://www.rosettagenomics.com/rosetta-genomics-and-microrna/

[Mathmos]

http://www.rosettagenomics.com/rosetta-genomics-and-its-classification-of-kidney-tumor/

[Mathmos]

6-Month-High is printing

Bid is stacking up. L2 without walls!

another trade, this time into the bid, but was not touching that 10k printing there again. MM games are on.

[Mathmos]

something is brewing here, it is a Q, but as a Shell with Mcap of 16.81k this is nuts in combination with the history of a former biotech giant

June the 6th got its highest Volume since April 16
nearly 13 x the average

https://twitter.com/TeddyShrbtsky74/status/1137049140704227337

[Mathmos]

short before a reorganisation?

https://twitter.com/TeddyShrbtsky74/status/1137047444414447622

[Mathmos]

https://asiancrunch.org/prostate-cancer-screening-market-astonishing-growthroche-diagnostics-rosetta-genomics-thermo-fisher-scientific/61417/

http://www.rosettagenomics.com/category/investors/

[Mathmos]

biggest volume since april 16 was yesterday. Bids are stacking up. Question of time to get new filings. Interest is growing on other big boards too.

[Coniba]

ROSGQ hmmmm. With these Q stocks getting custodianships… this one looks interesting

[makinezmoney]

$ROSGQ: NEWS..... $IDXG buys out Assets and Employees


Interpace Diagnostics (IDXG) Buys Select Assets of Rosetta Genomics Out of Bankruptcy


Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated bioinformatics and commercial company that provides clinically useful molecular diagnostic tests, related first line assessments and pathology services for improved patient diagnosis and management, today announced that it has successfully acquired a majority of the equipment of Rosetta Genomics’ Philadelphia laboratory through a bankruptcy auction. Interpace acquired, for an undisclosed amount of cash, 64 select lots of laboratory assets, including freezers, refrigerators, PCR machines, advanced slide scanning equipment as well as laboratory supplies and specialty furniture. The laboratory assets will further support the Company’s CLIA and CAP certified lab expansion in its Pittsburgh, PA and New Haven, CT laboratories.

Since the bankruptcy filing of Rosetta Genomics in May 2018, the Company has also hired several former key Rosetta employees and select former Rosetta customers have transitioned their accounts to Interpace’s thyroid assays. Interpace believes it is uniquely licensed to process thyroid slide biopsies, the primary specimen type for Rosetta’s Reveal™ product.

According to Jack Stover, President and CEO of Interpace, “We are proud to be serving many of the former Rosetta customers and are very pleased to have several highly-qualified Rosetta employees join the Interpace team. The cost effective, specialty equipment we acquired will be especially helpful as we continue to expand our new product offerings, including our slide products even further, under our combined ThyGeNEXT™ / ThyraMIR® assays for indeterminate thyroid nodules.”

[MOTSUR]

On watch list.

[makinezmoney]

$ROSGQ: I'm bidding.... gonna be a Winner


GO $ROSGQ... Fill my low order :)

[lennylovespenny]

Any news on the merger / chapter 7? also took a starter position in this.

[makinezmoney]

$ROSGF: They can provide a revised offer for $7Million

Bring it down a bit from the revised offer of $7Million.

Genoptix would be more receptive to that given the Share price TAKEDOWN
recently.

Actually, $ROSGF could actually just buyout all the shares on the
open market for a much cheaper price given that only 6Millon shares
are outstanding.

They could buy out the company for $3Million dollars which would send the
share price from here to $0.20-$0.30/sh


Worth the Gamble in my opinion. Already bought about 40k shares today
around $0.04. Will continue to buy more as it goes lower for a bit
more. A bounce is Definitely in the Books for this one.

Gonna play it.... thats How I make MONEY :)


GO $ROSGF

[KOmani]

You can read the link.

Company seems to be saying that beyond being a public shell, there is no assets.

[makinezmoney]

$ROSGF: Yes I know that.... Banking on Genoptix Buyout

Or even another offer that presents itself to bail them out.

They still hold IP.

Someone will come for that.


Thanks for the LINK !



****************************************************


( ROSG ROSGF ) Rosetta Announces That Completion of Genoptix Transaction UncertainFont size: A | A | A
5:51 PM ET 5/29/18 | Dow Jones
RELATED QUOTES


10:55 AM ET 6/4/18
Symbol Last % Chg
ROSGF
0.04 -48.53%
Real time quote.

Rosetta Contemplates Bankruptcy Filing May 31, 2018

PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / May 29, 2018 / Rosetta Genomics Ltd. (NASDAQ: ROSG; OTC PINK: ROSGF)(the "Company") announced today that the pending of merger of a subsidiary of Genoptix, Inc. with the Company has not occurred as scheduled and that Genoptix has refused to provide assurances that it intends to complete the transaction. Unless the transaction is completed by May 30, 2018, the Company intends to file for bankruptcy protection in Israel and the United States.

Genoptix has asserted the existence of a "Material Adverse Effect" affecting the Company and breaches of representations and warranties, which the Company disputes. The absence of a Material Adverse Effect since February 27, 2018, the date of the merger agreement, and continued accuracy of the Company's representations and warranties except as would not have a Material Adverse Effect are conditions to Genoptix's obligations to complete the transaction.

SOURCE: Rosetta Genomics Ltd

> Dow Jones Newswires

May 29, 2018 17:51 ET (21:51 GMT)

[KOmani]

Just an FYI.

The company went BK on May 31.

https://www.inforuptcy.com/filings/debke_173384-1-18-bk-11316-rosetta-genomics-inc

[makinezmoney]

$ROSGF: Getting some shares here at $0.04/sh

Looks like the Deal will go thru.

Should bounce back to $0.35/sh


GO $ROSGF